Ellen Weisberg
- Molecular Biology top 2%
- Hematology top 0.2%
- Genetics top 0.5%
- Oncology top 2%
- Rheumatology top 1%
- Co-authors
- James D. GriffinPaul W. ManleySandra W. Cowan‐JacobD. Gary GillilandArghya RayMalcolm WhitmanAndreas HochhausMartin Sattler
- Topics
- Chronic Myeloid Leukemia Treatments (49 papers)Chronic Lymphocytic Leukemia Research (35 papers)Acute Myeloid Leukemia Research (28 papers)
- Cited by
- HematologyGeneticsOncology
- Partner nations
- United StatesSwitzerlandChina
In The Last Decade
Ellen Weisberg
97 papers receiving 6.5k citations
Hit Papers
Peers
Comparison fields: 5 of 124
- Molecular Biology 3.7k
- Hematology 2.9k
- Genetics 1.6k
- Oncology 1.5k
- Rheumatology 760
Countries citing papers authored by Ellen Weisberg
This map shows the geographic impact of Ellen Weisberg's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Ellen Weisberg with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Ellen Weisberg more than expected).
Fields of papers citing papers by Ellen Weisberg
This network shows the impact of papers produced by Ellen Weisberg. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Ellen Weisberg. The network helps show where Ellen Weisberg may publish in the future.
Co-authorship network of co-authors of Ellen Weisberg
This figure shows the co-authorship network connecting the top 25 collaborators of Ellen Weisberg. A scholar is included among the top collaborators of Ellen Weisberg based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Ellen Weisberg. Ellen Weisberg is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
| # | Work | Indexed citations |
|---|---|---|
| 1 | 0 | |
| 2 | 2 | |
| 3 | 2 | |
| 4 | 14 | |
| 5 | 19 | |
| 6 | 19 | |
| 7 | 14 | |
| 8 | 38 | |
| 9 | 12 | |
| 10 | 76 | |
| 11 | 60 | |
| 12 | 66 | |
| 13 | 364 | |
| 14 | 46 | |
| 15 | Pharmacological profile of the FLT3-Tyrosine Kinase Inhibitor AST487 | 1 |
| 16 | AMN107: Inhibitory profile against non-mutated and mutated forms of the Bcr-Abl tyrosine kinase | 2 |
| 17 | Identification and characterization of a novel activating mutation of the FLT3 tyrosine kinase in AML | 3 |
| 18 | LAQ824 is a novel histone deacetylase inhibitor with significant activity against multiple myeloma: Results of a pre-clinical evaluation in vitro and in vivo. | 5 |
| 19 | 52 | |
| 20 | 23 |
About Ellen Weisberg
Ellen Weisberg is a scholar working on Hematology, Genetics and Rheumatology, having authored 99 papers that have together received 6.6k indexed citations. Recurring topics across this work include Chronic Myeloid Leukemia Treatments (49 papers), Chronic Lymphocytic Leukemia Research (35 papers) and Acute Myeloid Leukemia Research (28 papers). The work is most often cited by research in Hematology (2.9k citations), Genetics (1.6k citations) and Oncology (1.5k citations). Ellen Weisberg has collaborated with scholars based in United States, Switzerland and China. Frequent co-authors include James D. Griffin, Paul W. Manley, Sandra W. Cowan‐Jacob, D. Gary Gilliland, Arghya Ray, Malcolm Whitman, Andreas Hochhaus, Martin Sattler, Valérie Fridmacher and Xin Chen. Their work appears in journals such as Nature, Nature Medicine and Journal of Clinical Oncology.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.